When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months. The combination therapy shows durable efficacy and ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the ...

Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.

In 2025, significant changes will reshape healthcare for seniors in the United States, driven by the Inflation Reduction Act ...

AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).

In the ELEVATE-RR study, Calquence (acalabrutinib) matched Imbruvica (ibrutinib) when it came to keeping adults with previously treated, high-risk CLL alive without disease progression at a median ...

People with Medicare Part D plans shoulder a share of the cost of their prescription drugs. Under the standard Part D benefit ...

Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...

The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...